Myricx Bio Appoints Penny Fatato as Global Head of Clinical Operations as it Advances its NMTi-ADCs toward Clinical Development

London, UK, 18 August 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Penny Fatato in the newly created position of Global Head of Clinical Operations, based in Philadelphia, Pennsylvania, USA.

Penny Fatato brings over two decades of experience in clinical science and operations within the pharmaceutical industry across phase 1-4 clinical trials, with particular expertise in ADCs. She joins Myricx from Venatorx Pharmaceuticals, Inc. where she held the roles of Executive Director and Senior Director of Clinical Science. Prior to this she spent seven years at ADC Therapeutics, where she held various positions of increasing seniority, she played a critical role in advancing multiple oncology programs from early development through late-stage execution. Penny led global clinical operations strategy, overseeing cross-functional teams and external partners to ensure high-quality, efficient, and patient-focused trial delivery. Previous experience includes Chiltern, Morphotek, Wyeth, Teva and Aventis Behring following an earlier career in nursing. Penny holds a Bachelor of Science in Nursing from Penn State University and a certification in Clinical Research from Villanova University.

Steen Lisby, CMO of Myricx Bio said, “I am delighted to welcome Penny to the team. Her appointment further deepens the clinical expertise at Myricx as we scale to become a clinical stage company, with multiple N-myristoyltransferase inhibitor ADCs (NMTi-ADC) programs. Penny is our first US-based team member, reflecting our stage of growth and ambition.”

Penny Fatato, Global Head of Clinical Operations of Myricx Bio said, “Joining Myricx provides an exciting opportunity to apply my clinical trial management expertise alongside my experience advancing ADCs. I look forward to progressing our first-in-class, novel ADCs featuring Myricx’s unique NMTi payload technology into first-in-human clinical trials.”

Over the past 12 months since securing its £90 million ($114 million) Series A financing Myricx has moved to dedicated facilities in London, expanded its leadership and R&D teams and nominated its lead development candidate. It expects to enter human clinical trials in 2026 and plans further appointments in its leadership and teams both in the UK and the USA.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK-based biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).

Myricx is a spin out from Imperial College London and the Francis Crick Institute. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.

About N-myristoyltransferase inhibition

N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.

For further information please contact

At the Company
Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658